Undisclosed adenosine A2B receptor agonist / Lucy Therap - LARVOL DELTA

Lucy Therapeutics Secures New Funding to Advance New Alzheimer’s and Parkinson’s Treatments (Businesswire) - "Lucy Therapeutics...announced it has raised $12.5 million in additional funding led by existing investors Engine Ventures and Safar Partners with new participation from Bill Gates, Parkinson’s UK, and the Michael J. Fox Foundation, which provided a $2 million non-dilutive grant. The fresh capital brings LucyTx’s total funding to date to more than $36 million. The investments will further the company’s research programs for Alzheimer’s and Parkinson's diseases and continue its development of a novel drug target for Rett syndrome....Using a novel approach to understand the mitochondrial roots of complex diseases, the biotech startup has three drug discovery programs in its pipeline, with IND filings planned in 2025."

Financing • IND • Alzheimer's Disease • Parkinson's Disease